FDA 483 - The Procter & Gamble Company - August 23, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The Procter & Gamble Company, a dietary supplement own label distributor, was cited for significant quality control deficiencies. These included a failure to establish and follow written procedures for material review and disposition decisions, particularly concerning product specifications and oversight of contract manufacturers. Additionally, the firm's quality control operations for product complaints lacked human review and approval for investigation decisions, especially for non-critical complaints.
ID · e59db268-1a10-4ee5-a539-b249842f288c